000 01356 a2200397 4500
005 20250516052250.0
264 0 _c20120716
008 201207s 0 0 eng d
022 _a1573-7403
024 7 _a10.1007/s11102-011-0339-7
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBoguszewski, Cesar Luiz
245 0 0 _aA comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.
_h[electronic resource]
260 _bPituitary
_cMar 2012
300 _a44-9 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aBromocriptine
_xadministration & dosage
650 0 4 _aCabergoline
650 0 4 _aDopamine Agonists
_xadverse effects
650 0 4 _aEchocardiography
650 0 4 _aErgolines
_xadverse effects
650 0 4 _aFemale
650 0 4 _aHeart Valve Diseases
_xchemically induced
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aProlactinoma
_xdrug therapy
700 1 _ados Santos, Carlos Mauricio Correa
700 1 _aSakamoto, Kelly Suga
700 1 _aMarini, Lilian Cassia
700 1 _ade Souza, Admar Moraes
700 1 _aAzevedo, Monalisa
773 0 _tPituitary
_gvol. 15
_gno. 1
_gp. 44-9
856 4 0 _uhttps://doi.org/10.1007/s11102-011-0339-7
_zAvailable from publisher's website
999 _c21091236
_d21091236